louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03893656: Retroperitoneoscopic Donor Nephrectomy
Official title: Retroperitoneoscopic Donor Nephrectomy: a Retrospective Single-center Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Transplant; Complication, Failure
Keywords: Living donor nephrectomy
Kindey transplantation
Retroperitoneoscopic donor nephrectomy
Hernia
Lead sponsor: Samsun Liv Hospital
Sponsor class: OTHER
Collaborators: name: Ondokuz Mayıs University
First posted: 2019-03-28
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 57
Standard ages: ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 158 consecutive kidney donors undergoing pure RDN for allotransplantation at Ondokuz Mayıs University from January 2010 to August 2018. All operations were performed by a single surgeon (E. O.).

Brief summary: to compare the results of right and left-sided retroperitoneoscopic donor nephrectomy (RDN).

Detailed description: This was a retrospective study evaluating demographics, intraoperative and postoperative data of 158 kidney donors who underwent RDN from January 2010 to August 2018. Two groups were created according to the side of the surgery including Right RDN (group 1) and left RDN (group 2). The results of the recipients' were also evaluated.

Eligibility criteria: Inclusion Criteria:

* Adult donors
* Kidney donors undergoing retroperitoneoscopic donor nephrectomy
* Recipients of the kidneys
* Donors with the consent form
* Recipients with consent form

Exclusion Criteria:

* open donor nephrectomies
* donors without the consent form
* Recipients without the consent form

Primary outcomes:
measure: Operation time
timeFrame: at the end of the surgery
measure: Blood loss
timeFrame: at the end of the surgery
measure: warm ishemia time
timeFrame: at the end of the surgery
measure: İntraoperative complications
timeFrame: at the end of the surgery
measure: incisional hernia
timeFrame: up to 2 years
measure: postoperative complication
timeFrame: up to 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Samsun Liv Hospital
city: Samsun
country: Turkey
facility: Ondokuz Mayıs University
Study officials:
affiliation: Ondokuz Mayıs University
name: Saban Sarıkaya, Professor
role: STUDY_CHAIR
References:
citation: Ratner LE, Ciseck LJ, Moore RG, Cigarroa FG, Kaufman HS, Kavoussi LR. Laparoscopic live donor nephrectomy. Transplantation. 1995 Nov 15;60(9):1047-9.
citation: Hsu JW, Reese PP, Naji A, Levine MH, Abt PL. Increased early graft failure in right-sided living donor nephrectomy. Transplantation. 2011 Jan 15;91(1):108-14. doi: 10.1097/TP.0b013e3181fd0179.
citation: Kumar A, Chaturvedi S, Gulia A, Maheshwari R, Dassi V, Desai P. Laparoscopic Live Donor Nephrectomy: Comparison of Outcomes Right Versus Left. Transplant Proc. 2018 Oct;50(8):2327-2332. doi: 10.1016/j.transproceed.2018.03.034. Epub 2018 Mar 16.
Clinical trial NCT04586556: Artificial Intelligence for Real-time Detection and Monitoring of Colorectal Polyps
Official title: Artificial Intelligence for Real-time Detection and Monitoring of Colorectal Polyps
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenomatous Polyps
Keywords: Polyps detection
Artificial Intelligence
Adenoma detection
Polyps classification
Quality indicators
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 372
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: prospective, multi-endoscopist, single center, clinical study at tertiary referral center (CHUM)
Primary purpose: DIAGNOSTIC

Brief summary: The investigators hypothesize that the clinical implementation of a deep learning AI system is an optimal tool to monitor, audit and improve the detection and classification of polyps and other anatomical landmarks during colonoscopy. The objectives of this study are to generate preliminary data to evaluate the effectiveness of AI-assisted colonoscopy on: a) the rate of detection of adenomas; b) the automatic detection of the anatomical landmarks (i.e., ileocecal valve and appendiceal orifice).

Detailed description: In this trial, the investigators aim to evaluate the followings:

1. the accuracy of automatic detection of important anatomical landmarks (i.e., ileocecal valve, appendiceal orifice);
2. the accuracy of automatic detection of polyps/adenomas (PDR/ADR);

Eligibility criteria: Inclusion Criteria :

* Signed informed consent
* Age 45-80 years
* Indication to undergo a lower GI endoscopy.

Exclusion Criteria :

* Coagulopathy
* Poor general health, defined as an American Society of Anesthesiologists (ASA) physical status class \>3
* Emergency colonoscopies
* Hospitalized patients
* Known inflammatory bowel disease (IBD)
* Patients currently in the emergency room

Primary outcomes:
measure: Number of polyps detected
timeFrame: Day 1
measure: Evaluation of the automatic report of the colonoscopy quality indicators
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: Université de Montréal
state: Quebec
city: Montréal
country: Canada
facility: Centre Hospitalier Universitaire de Montréal
state: Quebec
city: Strasbourg
country: France
facility: IHU Strasbourg
Study officials:
affiliation: Centre hospitalier de l'Université de Montréal (CHUM)
name: Daniel von Renteln
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03185156: The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate
Official title: The Preventive Effect of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Nausea and Vomiting
Keywords: nausea and vomiting
hemabate
propofol
Lead sponsor: West China Second University Hospital
Sponsor class: OTHER
First posted: 2017-06-14
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 60 maternal aged 20-40 years will be collected
Primary purpose: PREVENTION

Brief summary: This is a randomized, placebo-controlled trail, the objective of this study is observation the effect of sub hypnotic dose of propofol for prevention of nausea and vomiting induced by hemabate during spinal anesthesia for elective cesarean section. The primary outcome is the presence of post-delivery intra-operative nausea and vomiting in parturients. The patients demographic characteristics, blood pressure, sensory block level, and the medications will be collected.


Eligibility criteria: Inclusion Criteria:

* Patients aged 20-40 years;
* American Standards Association status I-II.

Exclusion Criteria:

* Patients with allergy or hypersensitivity to propofol, lipid emulsion, or granisetron;
* History of nausea or vomiting within 24h before cesarean delivery;
* History of gastrointestinal or psychiatric disease, motion sickness, smoking, postoperative nausea and vomiting;
* Morbid obesity;
* Consumption of drugs such as opioids, antiemetics , H2 antagonists, phenothiazines and/or corticosteroids within 24h before the study period;
* Any chronic medical or surgical disorders complicating the pregnancy;
* Conditions contraindicating regional anesthesia.

Primary outcomes:
measure: The presence of nausea and vomiting
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Second University Hospital
state: Sichuan
Study officials:
References:
citation: Bi Y, Zhong R, Huang J, Huang H. Effect of continuous infusion of a subhypnotic dose of propofol on nausea and vomiting after carboprost administration at cesarean delivery: A randomized, double-blind, placebo-controlled trial. Int J Gynaecol Obstet. 2022 May;157(2):283-288. doi: 10.1002/ijgo.13742. Epub 2021 Jun 9.
Clinical trial NCT00793156: A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Official title: A Randomized-Withdrawal Phase 3 Study Evaluation the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Uremic Pruritus
Keywords: uremic pruritus
Lead sponsor: Acologix, Inc.
Sponsor class: INDUSTRY
First posted: 2008-11-19
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with moderate to severe itching associated with end-stage renal disease and hemodialysis, and perform a population PK analysis.


Eligibility criteria: Inclusion Criteria:

* 18 yrs old or older
* moderate to severe pruritus
* end stage renal disease
* 3x weekly hemodialysis

Exclusion Criteria:

* pruritus not due to renal disease
* abnormal liver function
* Ca-P \> 80 mg/dl or HgB \<8.5 g/dl or PTH \> pg/mL
* Within four months spKt/V \< 1.05

Primary outcomes:
measure: Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period.
timeFrame: 11 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2.
Clinical trial NCT00518856: Lufwanyama Neonatal Survival Project
Official title: Lufwanyama Neonatal Survival Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mortality
Keywords: birth asphyxia
neonatal sepsis
maternal to child transmission of HIV
Lead sponsor: Boston University
Sponsor class: OTHER
Collaborators: name: Tufts University
First posted: 2007-08-21
Enrollment: 3559
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.

Detailed description: This is a cluster randomized trial of the impact of providing additional training and supplies to traditional birth attendants in a rural setting in Zambia. 120 TBAs are randomized into intervention/control. Intervention TBAs receive NRP training, supplies for neonatal resuscitation, receiving blankets for thermoregulation, and amoxicillin tablets. Control TBAs continue according to prior standard of care. Primary outcome is mortality at 28 days life as a proportion of births attended by TBAs in each study arm.

Eligibility criteria: Inclusion Criteria:

* TBA trained in safe delivery;
* willing to sign informed consent; willing to be randomized; willing to adhere to study procedures

Exclusion Criteria:

* TBA living outside of Lufwanyama district

Primary outcomes:
measure: mortality
timeFrame: day 28
Secondary outcomes:
measure: perinatal mortality
timeFrame: day zero
measure: sepsis mortality
timeFrame: deaths between days 1-28
measure: cost effectiveness
timeFrame: days 0-28
measure: successful delivery of nevirapine prophylaxis to HIV exposed deliveries
timeFrame: day zero umbilical cord dried blood spot
Other outcomes:
Locations:
Study officials:
affiliation: Boston Universtiy
name: Christopher J Gill, MD MS
role: PRINCIPAL_INVESTIGATOR
affiliation: Lufwanyama District Health Management Team
name: Grace Mazala, RN
role: STUDY_DIRECTOR
References:
citation: Gill CJ, Guerina NG, Mulenga C, Knapp AB, Mazala G, Hamer DH. Training Zambian traditional birth attendants to reduce neonatal mortality in the Lufwanyama Neonatal Survival Project (LUNESP). Int J Gynaecol Obstet. 2012 Jul;118(1):77-82. doi: 10.1016/j.ijgo.2012.02.012. Epub 2012 Apr 27.
citation: Gill CJ, Phiri-Mazala G, Guerina NG, Kasimba J, Mulenga C, MacLeod WB, Waitolo N, Knapp AB, Mirochnick M, Mazimba A, Fox MP, Sabin L, Seidenberg P, Simon JL, Hamer DH. Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study. BMJ. 2011 Feb 3;342:d346. doi: 10.1136/bmj.d346.
Clinical trial NCT05558956: Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
Official title: Total Body PET-CT Imaging of Prostate Cancer Using Illuccix (Kit for the Preparation of Ga-68 PSMA-11 Injection)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Metastatic Castration-resistant Prostate Cancer
Lead sponsor: BAMF Health
Sponsor class: OTHER
Collaborators: name: Telix Pharmaceuticals (Innovations) Pty Limited
First posted: 2022-09-28
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.


Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Male ≥ 18 years of age
3. Patients meeting clinical need for Illuccix PET scan:

   1. Patients with suspected metastasis who are candidates for initial definitive therapy
   2. Patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
4. Patient is physically able to lay flat for the PET-CT procedure

Exclusion Criteria:

1. Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.

Primary outcomes:
measure: Comparing the imaging quality using low dose and high dose Ga-68 PSMA-11 at various scan lengths.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Grand Rapids
country: United States
facility: BAMF Health
state: Michigan
Study officials:
References:
Clinical trial NCT02268656: Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction With a Single-dose Dexmedetomidine
Official title: Preducted Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Igel
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2014-10-20
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Before anethetic induction, infuse dexmedetomidine 0.5 mcg/kg for 2 minutes and after injection of lidocaine 30 mg, propofol infusion by using target controlled infusion (TCI) pump. Effect site concentraion of propofol start from 5 and changes the concentration as previous response to i-gel insertion as up and down methods

Detailed description: Before anethetic induction, infuse dexmedetomidine 0.5 mcg/kg for 2 minutes and after injection of lidocaine 30 mg, propofol infusion by using target controlled infusion (TCI) pump. Effect site concentraion of propofol start from 5 and changes the concentration as previous response to i-gel insertion as up and down methods. Failure of previous subjects are defined as difficulty to mouth open, severe nausea and couph and laryngeal spasm, and not loss of consciousness.

Eligibility criteria: Inclusion Criteria:

* ASA PS I-II, 20-60 yrs old

Exclusion Criteria:

* predicted difficulty airway, recent URI, BMI \> 30kg/m2, reactive airway disease

Primary outcomes:
measure: Concentration of Propofol
timeFrame: from i-gel insertion up to 5 min
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Choi JJ, Kim JY, Lee D, Chang YJ, Cho NR, Kwak HJ. Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 mug/kg. BMC Anesthesiol. 2016 Mar 22;16:20. doi: 10.1186/s12871-016-0186-1.
Clinical trial NCT00284856: Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
Official title: A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2006-02-01
Enrollment: 1640
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter study to evaluate the efficacy and safety of MK0476 versus placebo in participants with chronic asthma who actively smoke cigarettes.


Eligibility criteria: Inclusion Criteria:

* Participants with chronic asthma who actively smoke at least 0.5 to no more than 2 packs of cigarettes a day

Exclusion Criteria:

* Participant cannot have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or emphysema.

Primary outcomes:
measure: Percentage of Asthma-control Days Over the 6-month Treatment Period
timeFrame: 6 months
Secondary outcomes:
measure: Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period
timeFrame: Baseline and 6 months
measure: Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period
timeFrame: Baseline and 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013 Mar;131(3):763-71. doi: 10.1016/j.jaci.2012.12.673. Epub 2013 Feb 4.
Clinical trial NCT06065956: Comparison of Hemodynamic Changes With Morphine Versus Esmolol During Induction of Anaesthesia
Official title: Comparison of Hemodynamic Changes With Morphine Versus Esmolol as an Adjuvant Agent During Induction of Anaesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Intubation Complication
Lead sponsor: Pakistan Navy Station Shifa Hospital
Sponsor class: OTHER
First posted: 2023-10-04
Enrollment: 110
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Comparing hemodynamic changes with morphine versus esmolol as an adjuvant agent during induction of Anaesthesia

Detailed description: Comparing hemodynamic profile of patients during induction of General Anesthesia with intravenous morphine as an adjuvant drug versus Intravenous esmolol as an adjuvant agent,My aim is to study which drug has superior hemodynamic profile in terms of hemodynamic stability of patient requiring General Anesthesia.

Eligibility criteria: Inclusion Criteria:

* ASA 2 patients presenting for elective surgery.

Exclusion Criteria:

* Patients having major cardiac disease.
* Metastatic disease.
* Pregnant females.
* Those unwilling to be part of study.

Primary outcomes:
measure: Blood pressure
timeFrame: 06 months
measure: Pulse rate
timeFrame: 06 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: PNS Shifa Hospital
state: Sind
Study officials:
References:
Clinical trial NCT01215656: Effect of a Follow on Formula With Lactobacillus Fermentum on the Incidence of Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Incidence of Infectious Diseases
Lead sponsor: Puleva Biotech
Sponsor class: INDUSTRY
First posted: 2010-10-06
Enrollment: 188
Sex: ALL
Minimum age (years): 6
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of the study is to evaluate the effects of a follow on formula containing the human milk probiotic Lactobacillus fermentum on the incidence of infection in 6 months old infants.


Eligibility criteria: Inclusion Criteria:

* 6 months old children born at term
* written consent from parents

Exclusion Criteria:

* frequent gastrointestinal disorders (frequent diarrhoeas, constipation episodes, gastroesophageal reflux)
* gastrointestinal surgery
* cow's milk protein allergy
* metabolic diseases (diabetes or lactose intolerance)
* immune deficiency
* antibiotic treatment during the trial and/or recent (within the preceding 3 weeks)

Primary outcomes:
measure: Incidence of infectious diseases
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Maldonado J, Canabate F, Sempere L, Vela F, Sanchez AR, Narbona E, Lopez-Huertas E, Geerlings A, Valero AD, Olivares M, Lara-Villoslada F. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):55-61. doi: 10.1097/MPG.0b013e3182333f18.
Clinical trial NCT01040156: Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
Official title: Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Systemic Aspergillosis
Systemic Candidiasis
Lead sponsor: University Children's Hospital Tuebingen
Sponsor class: OTHER
First posted: 2009-12-29
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients undergoing allogeneic stem cell transplantation

Brief summary: Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients under the age of 18 years
* Pediatric patients after HSCT treated with caspofungin
* Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion Criteria:

* Pediatric patients with uncontrolled hematological malignancies
* Pediatric patients with IFI at start of HSCT

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Children's Hospital
Study officials:
affiliation: UCHT
name: Ingo Mueller, M.D.
role: PRINCIPAL_INVESTIGATOR
References: